Gastrointestinal Organoid Biobank
What are Patient Derived Organoids?
Patient derived organoids (PDOs) are novel in vitro 3D cell models that preserve original tissue physiology and molecular pathology, thus representing a clinically-relevant alternative to traditional 2D cell lines and an effective tool to refine and reduce animal models. PDOs can be derived from adult patient biopsies or resected tissues containing native LGR5+ stem cell populations and cultured within an ECM-rich substrate using specialized organoid media such as L-WRN conditioned media (SCM105). Adult tissue derived organoids are phenotypically and genetically stable in long term culture, presenting more mature phenotypes compared to iPSC-derived organoids. Importantly, PDOs have shown to be able to predict patient clinical responses to chemotherapeutic.
Gastrointestinal Organoid Biobank
We are now offering a comprehensive biobank of highly characterized tissue-derived human gastrointestinal organoids from normal and diseased patients. The intestinal organoid biobank contains over 50 highly characterized intestinal organoids from both normal and diseased patients derived from multiple regions of the digestive systems including small intestine (duodenum, ileum), stomach, rectum and colon.
3dGRO™ organoids were derived utilizing HUB Organoid Technology. The purchaser of this product shall agree to HUB’s terms of use, which shall be separately acknowledged and accepted by such purchaser, prior to transfer of this product to purchaser.
Biobank Overview
- 58 Patient Derived Organoid Samples
- Multiple Genders, Age, and Sex
- Multiple Tissues/Diseases: Colon, Duodenum, Ilium, Stomach, Rectum, Cancer, Ulcerative Colitis, IBS
- RNA-Seq Available
- Low Passage and High Viability
- Cultured in Optimized 3dGRO™ L-WRN Conditioned Media
Prep-78-C (SCC311)
Prep-87-C (SCC321)
Prep-81-C (SCC313)
14-881-CR (SCC310)
Normal Gastrointestinal PDOs
ID | Catalog Number | Age | Sex | Organ | Disease Type or Normal |
---|---|---|---|---|---|
Prep 78-C | SCC311 | 52 | F | Colon | Normal (RNA-seq) |
Prep 80-C | SCC312 | 29 | F | Colon | Normal (RNA-seq) |
Prep 81-C | SCC313 | 49 | F | Colon | Normal (RNA-seq) |
Prep 81-D | SCC314 | 49 | F | Duodenum | Normal (RNA-seq) |
Prep 83-C | SCC315 | 45 | F | Colon | Normal (RNA-seq) |
Prep 83-D | SCC316 | 45 | F | Duodenum | Normal (RNA-seq) |
Prep 84-C | SCC317 | 56 | F | Colon | Normal (RNA-seq) |
Prep 84-D | SCC318 | 56 | F | Duodenum | Normal (RNA-seq) |
Prep 85-C | SCC319 | 62 | F | Colon | Normal (RNA-seq) |
Prep 85-D | SCC320 | 62 | F | Duodenum | Normal (RNA-seq) |
Prep 87-C | SCC321 | 21 | M | Colon | Normal (RNA-seq) |
Prep 87-D | SCC322 | 21 | M | Duodenum | Normal (RNA-seq) |
Prep 88-C | SCC323 | 33 | F | Colon | Normal (RNA-seq) |
Prep 88-D | SCC324 | 33 | F | Duodenum | Normal (RNA-seq) |
Prep 89-C | SCC325 | 55 | M | Colon | Normal (RNA-seq) |
Prep 89-D | SCC326 | 55 | M | Duodenum | Normal (RNA-seq) |
18-1417-N | SCC327 | 45 | M | Colon | Normal (CRC tissue adjacent) (RNA-seq) |
ht-099-C | SCC330 | 59 | F | Colon | Normal (RNA-seq) |
ht-101-C | SCC332 | 59 | F | Colon | Normal (RNA-seq) |
ht-103-C | SCC335 | 63 | M | Colon | Normal (RNA-seq) |
ht-104-C | SCC336 | 51 | M | Colon | Normal (RNA-seq) |
ht-104-I | SCC337 | 51 | M | Ileum | Normal (RNA-seq) |
ht-105-C | SCC338 | 19 | M | Colon | Normal (RNA-seq) |
ht-105-I | SCC339 | 19 | M | Ileum | Normal (RNA-seq) |
ht-118-C | SCC340 | 43 | M | Colon | Normal |
ht-119-C | SCC341 | 53 | F | Colon | Normal |
ht-127-S | SCC342 | 52 | F | Stomach | Normal |
ht-128-S | SCC343 | 60 | F | Stomach | Normal |
ht-129-S | SCC344 | 60 | M | Stomach | Normal |
ht-130-S | SCC345 | 68 | M | Stomach | Normal |
ht-215-CD | SCC346 | 59 | F | Colon Descending | Normal |
ht-215-CT | SCC347 | 59 | F | Colon Transcending | Normal |
ht-215-D | SCC348 | 59 | F | Duodenum | Normal |
ht-222-D | SCC349 | 33 | M | Duodenum | Normal |
ht-180-D | SCC350 | 38 | F | Duodenum | Normal |
ht-185-D | SCC351 | 45 | M | Duodenum | Normal |
ht-188-D | SCC352 | 50 | F | Duodenum | Normal |
ht-205-CS | SCC353 | 33 | F | Colon Sigmoid | Normal Margin to Crohns (RNA-seq) |
ht-205-D | SCC354 | 33 | F | Duodenum | Normal Margin to Crohns |
ht-205-I | SCC355 | 33 | F | Ileum | Normal Margin to Crohns |
ht-213-CA | SCC356 | 36 | F | Colon Ascending | Normal margin to UC |
ht-213-CD | SCC357 | 36 | F | Colon Descending | Normal margin to UC |
ht-213-CT | SCC358 | 36 | F | Colon Transcending | Normal margin to UC |
ht-213-D | SCC359 | 36 | F | Duodenum | Normal margin to UC |
ht-214-I | SCC360 | 46 | M | Ileum | Normal margin to UC |
ht-227-D | SCC362 | 62 | M | Duodenum | Normal margin to UC |
ht-230-D | SCC363 | 59 | F | Duodenum | Normal margin to UC |
ht-506-I | SCC368 | 34 | F | Ileum | Normal Margin to Crohns |
ht-352-D | SCC370 | 55 | F | Duodenum | Normal |
CSC.406N | SCC725 | 69 | F | Colon | Normal (CRC tissue adjacent) |
CSC.421N | SCC726 | 83 | F | Colon | Normal (CRC tissue adjacent) |
CSC.449N | SCC727 | 40 | M | Colon | Normal (CRC tissue adjacent) |
Adenoma and Adenocarcinoma Gastrointestinal PDOs
ID | Catalog Number | Age | Sex | Organ | Disease Type or Normal |
---|---|---|---|---|---|
14-881-CR | SCC310 | 46 | M | Colon (Rectum) | Adenocarcinoma (TP53 Pro151Ser, KRAS Gly12Asp, APC Pro1443fs) (RNA-seq) |
ht-131-C | SCC328 | 58 | F | Colon | Adenoma |
CSC.240 | 83 | M | Colon | Adenocarcinoma | |
POP.024.G4 | 66 | M | Colon | Adenocarcinoma, metastatic (liver) | |
CSC.073.G1 | 67 | M | Colon | Adenocarcinoma, metastatic (lung) | |
POP.074.G4 | 86 | M | Colon | Adenocarcinoma | |
POP.112.G2 | 74 | M | Colon | Adenocarcinoma | |
POP.161.G1 | 60 | F | Colon | Adenocarcinoma, metastatic (lung) | |
POP.141.G2 | 57 | M | Colon | Adenocarcinoma, metastatic (liver) | |
POP.174.G1 | 56 | M | Colon | Adenocarcinoma, metastatic (lung) | |
POP.170 | 61 | M | Colon | Adenocarcinoma, metastatic (liver) | |
POP.066.G4 | 46 | F | Colon | Adenocarcinoma, metastatic (liver) | |
POP.092.G2 | 46 | F | Colon | Adenocarcinoma | |
POP.160.G2 | 69 | M | Colon | Adenocarcinoma, metastatic (liver) | |
CSC.171C.G1 | 47 | F | Colon | Adenocarcinoma | |
CSC.171L.G1 | 47 | F | Colon | Adenocarcinoma, metastatic (liver) | |
CSC.413 | 43 | M | Colon | Adenocarcinoma | |
CSC.456 | 68 | M | Colon | Adenocarcinoma, metastatic (liver) | |
CSC.463 | 43 | F | Colon | Adenocarcinoma, metastatic (lung) |
Colorectal Cancer Gastrointestinal PDOs
ID | Catalog Number | Age | Sex | Organ | Disease Type or Normal |
---|---|---|---|---|---|
ISO34 | SCC500* | N/A | N/A | Sigmoid Colon | Colorectal Cancer (APC ∆E1451*, BRAF ∆K601E) |
ISO38 | SCC501* | N/A | N/A | Sigmoid Colon | Colorectal Cancer (TP53 Pro151Ser, KRAS Gly12Asp, APC Pro1443fs) |
ISO48 | SCC502* | N/A | N/A | Caecum | Colorectal Cancer (PIK3CA ∆E542K, CTNNB1 ∆S33C) |
ISO49 | SCC503* | N/A | N/A | Lower Sigmoid Colon | Colorectal Cancer (APC ∆R1450*A1446Lfs*27, TP53 ∆R248Q, KRAS ∆G12D, PIK3CA ∆E542K, FBXW7 ∆R465C) |
ISO50 | SCC504* | N/A | N/A | Colon (Rectum) | Colorectal Cancer (APC ∆R232*E1286*, TP53 ∆R248Q", KRAS ∆G12D, SMAD4 ∆E526K, SMAD2 ∆S464*) |
ISO57 | SCC505* | N/A | N/A | Colon (Upper Rectum) | Colorectal Cancer (APC ∆Q978*, TP53 ∆R282W, KRAS ∆G13D) |
ISO68 | SCC506* | N/A | N/A | Sigmoid Colon | Colorectal Cancer (APC ∆Q1096*E1408*, TP53 ∆R248W, KRAS ∆G13D, SMAD4 ∆Q534*) |
ISO72 | SCC507* | N/A | N/A | Caecum | Colorectal Cancer (APC ∆Q1291*, KRAS ∆G12D, ERBB3 ∆A232V) |
Crohn’s Disease and Ulcerative Colitis Gastrointestinal PDOs
ID | Catalog Number | Age | Sex | Organ | Disease Type or Normal |
---|---|---|---|---|---|
ht-206-CR | SCC365 | 24 | F | Colon | Crohns (RNA-seq) |
ht-206-I-CR | SCC366 | 24 | F | Ileum | Crohns |
ht-208-CR-CR | SCC367 | 23 | M | Colon (Rectum) | Crohns (RNA-seq) |
ht-506-I | SCC368 | 34 | F | Ileum | Normal Margin to Crohns |
ht-405-CA-UC | SCC369 | 36 | F | Colon Ascending | Ulcerative Colitis |
Figure 2.Immunocytochemical characterization of human colon organoids (Colon-87, SCC321). Human colon PDOs are positive for colon-specific markers: CA II, CA IV and Mucin5B, posterior hindgut marker: CDX2, stem cell markers: Lgr5 and Sca1 and epithelial markers: TPH-1 and E-Cad.
Figure 3.Heatmap of top 30 differentially expressed genes.
hiPSC | Gene Name | Human iPSC (Average) | Patient-derived Colon Organoids (Average) | Human iPSC-derived Colon Organoids (Average) | Gene Characteristics |
---|---|---|---|---|---|
Genes Overexpressed in Colon Organoids Relative to hiPSC | TJP3 | 664 | 4932 | 4401 | Tight Junction protein ZO-3 |
CDKN1A | 793 | 7570 | 11107 | Cyclin dependent kinase inhibitor 1A | |
EPHB2 | 784 | 2608 | 2372 | Ephrin type B receptor 2 | |
ALDH1A1 | 64 | 6601 | 21930 | Aldehyde Dehydrogenase 1 | |
LGR5 | 2 | 503 | 524 | Intestinal stem cell biomarker | |
MYC | 1142 | 2828 | 2661 | Proto-oncogene | |
CDX2 | 4 | 1399 | 3980 | Intestine-specific transcription factor | |
KRT20 | 2 | 162 | 6027 | Type 1 cytokeratin; major protein of mature enterocytes and goblet cells | |
BMP2 | 169 | 827 | 2910 | TGFb signaling pathway | |
LY6E | 2555 | 10162 | 36304 | Associated with drug resistance & tumor immune escape in breast cancer | |
EPHB3 | 61 | 4652 | 337 | Ephrin type B receptor 3 | |
MUC5B | 7 | 935 | 48 | Encodes respiratory tract mucin glycoprotein | |
MUC2 | 1 | 9 | 126 | Secreted from goblet cells; gel provides insoluble mucous barrier to protect intestinal epithelium | |
CA2 | 126 | 200 | 2207 | Carbonic anhydrase II, enzyme expressed in many tissues, including GI tract | |
CDH1 | 8052 | 10517 | 20622 | Epithelial cadherin; E-cadherin | |
Lower Expressed Genes Relative to hiPSC | DCLK1 | 1942 | 4 | 2 | Microtubule associated protein kinase; tuft cell marker in the small intestine |
CCNA2 | 4002 | 1226 | 1008 | Cyclin A2 | |
TAGLN | 4460 | 184 | 94 | Actin cross-linking/gelling protein involved in Ca interactions and contractile properties of cell | |
PLK1 | 5077 | 1513 | 1221 | Early trigger for G2/M transition | |
CDC20 | 5093 | 2198 | 1257 | Involvement in pathway protein ubiquitination | |
GNA14 | 711 | 9 | 74 | G-protein family member |
Figure 4.Adult tissue derived colon (SCC321, Colon-87) and duodenum (SCC320, DUO-85) organoids express SARS-CoV-2 related proteins ACE2 and TMPRSS2.
Figure 5.Forskolin-induced swelling of duodenum gut organoids (SCC314, DUO-81). The total organoid area increase relative to T=0 of FSK treatment was calculated and averaged from 10 individual cysts per condition. Scale bars = 500 um.
Figure 6.Generation of apical out illeum gut organoids (SCC339, HT-105-I). Apical out organoids were stained with dapi (blue) and ZO-1 (Green) antibodies to analyze efficiency of epithelial polarity reversion.
To continue reading please sign in or create an account.
Don't Have An Account?